Tasco Holdings (fka THII)

[phoenixdove]

What happens now with Frezer Inc shares - will they ever be registered?

[BULListic]

Lebed pumping...er profiling, THII:

After sending this alert I am going to purchase a few THII shares in the open market.
This is a huge vacation week along with a holiday and back to school for most of the country.
Trading is slower for many companies. This is not a bad thing and is an opportunity for those members who are still at home and still working. Lots of people expect the market to come back with a vengeance next week as people get back to work. I believe the market will be incredible this year due to the slump in real estate. I think much of that money will come back into the markets.
We are about to do a major investor relations campaign for THII.
I think yesterdays news told us that THII is ramping up for the opening of their new facility. This will be a HUGE moment for THII. My group is one of the first to know about this company, but not for long! THII is approximately ONE MONTH away from its opening! I hope you understand what that means.
I discussed THII briefly this past weekend because of the stem cell play ACTC that ran last week, but we are holding everything off until next week after the Holiday.
THII isn't trading a lot of volume yet but this is a good thing. The stock only has 2.78 million in the float. This means that when the volume does come in, it could potentially make a huge move quick.
I believe THII is at least going to $6 where Beacon Research has their target price. Once it moves higher I wouldn't be surprised to see them raise their target price.
Take a look at the press releases and listen to the interviews conducted in the recent days. While all of this may seem very minor, it is a build up to the big events that are about to take place.
THII will be opening, in the upcoming weeks, the premiere adult stem cell from fat facility in this entire country. THII will have the only Adipose Adult Stem Cell Bank in this country and will be one of a hand full of facilities that store cord blood.
There is no controversy surrounding THII like there is with other stem cell companies because THII is using stem cells from fat and not killing or destroying any embryos.
THII has their own proprietary technology that nobody else has. THII has already developed approximately 192 disposable instruments for extracting stem cells from adipose fat.
Take a look at this article here about how doctors used stem cells from fat to repair a girl's skull. The damaged bone actually grew back!
http://www.msnbc.msn.com/id/6727466/
Also read this article about how cord blood was used to make a paralyzed woman walk again!
http://www.rideforlife.com/news/stem_cell_research/paralyzed_woman_walks_again_after_stem_cell_thera...
Isn't all of this unbelievable! I believe THII is going to play an important role in using stem cells to save so many lives in the future. One of those lives could by yours or mine. I think THII deserves everyone's attention now.
-----
My firm Lebed Biz LLC has been compensated by a third-party (DML Marketing) $25,000 cash for a one-month THII investor relations contract. We expect to receive additional compensation which can be equal to ten percent of any newly issued or registered stock in THII. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: http://www.lebed.biz/disclaimer.htm
Jonathan Lebed
Lebed.biz

[lady*b]

Tasco Holdings Files to Change Name to Bio-Matrix Scientific Group Inc.
Monday August 28, 11:30 am ET
Company Has 15,000 Sq. Ft. Stem Cell Banking Facility


SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2006--Tasco Holdings International (OTCBB:THII - News) announced today that it has filed to change its name to Bio-Matrix Scientific Group Inc. This move is in concert with the recent acquisition of assets from BMXP Holdings Inc. (symbol: BXPH) previously announced. Once all the filings have been finalized it is anticipated the company will trade under a new symbol reflective of its new name.


A company spokesperson said, "We are in the process of changing the Company's name to continue the Bio-Matrix brand in the adult stem cell banking arena."

The Company's Chairman & CEO David Koos stated, "We are excited about the Company's future with the continuation of Bio-Matrix' recognition in stem cell banking and stem cell / tissue management instruments. We believe the Company's new 15,000 sq. ft. facility should be completed shortly sometime in early October 2006. These two events, we believe, will lead to Bio-Matrix' brand development and near term realization of revenue."

Brian Pockett, Managing Director & COO for Tasco, noted, "The name 'Bio-Matrix Scientific Group' better denotes our company's business model. All of us associated with the Company are excited about the milestones we have achieved in a very short period of time."

BMXP Holdings Inc. - formerly Bio-Matrix Scientific Group Inc. (symbol: BXPH) is the largest shareholder of Tasco Holdings International (OTCBB:THII - News). BMXP Holdings owns 10 million common shares of Tasco as a result of the sale of its wholly-owned subsidiary to Tasco on July 3, 2006.

Mr. Koos and Mr. Pockett concurrently serve as Chairman / CEO and Director / Vice President respectively of both Tasco Holdings International (OTCBB:THII - News) and BMXP Holdings Inc. (symbol: BXPH).

DISCLAIMER:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.



Contact:
AGORA Investor Relations:
[e-mail]
http://www.agoracom.com/IR/Bio-Matrix

--------------------------------------------------------------------------------
Source: Tasco Holdings International

http://biz.yahoo.com/bw/060828/20060828005417.html?.v=1

[JJdivini]

COMPANY SPOTLIGHT - THII

Tasco Holdings International (OTCBB:THII),

a biotechnology company focused on stem cell cryogenics and disposable stem cell
/ tissue transfer instruments


*************

Why is there such controversy surrounding stem cells?

When stem cells are taken from an embryo, the embryo is destroyed. That's
abhorrent to people who consider an embryo to be developing human life.
President Bush has restricted federal money for research into embryonic stem
cells.

The big news last week was that scientists have discovered a way to create human
stem cells by taking one cell from the embryo without destroying the embryo.

While this is incredible news, it certainly will not end all of the controversy.

The Vatican just came out today and said that this new method of making stem
cells is manipulation of the embryo and does not address ethical concerns.

http://news.yahoo.com/s/nm/20060826/ts_nm/religion_stemcell_dc_1

THII doesn't use embryonic stem cells.
THII uses adult stem cells from fat.

Reprogrammable Cells From Fat Are True Adult Stem Cells
http://www.sciencedaily.com/releases/2004/03/040309074344.htm

"Adult" stem cells, are different from the controversial embryonic stem cells.
Some who oppose research into embryonic stem cells, champion the cause of adult
stem cells.

Scientist report that introducing only four genes to adult cells is sufficient
to convert them to something that looks and acts remarkably like an embryonic
stem cell. This may allow the production of an essentially unlimited supply of
stem cells.

Fat has "certainly been overlooked as a potential source of stem cells," says
Dr. Adam Katz, a plastic surgeon who studies the fat-derived cells at the
University of Virginia. Actually, it's probably the most practical source, he
said.

There's good evidence the fat-derived cells can morph into bone, cartilage,
skeletal muscle, blood vessel tissue and fat, at least in the laboratory, with
suggestive evidence they can also turn into heart muscle and nerve cells.

Dr. Kai Pinkernell, a cardiovascular researcher at Tulane University, says he
found an encouraging result in pigs that were given experimental heart attacks.
When he took fat-derived cells from the pigs and put them into the hearts of the
same donor animals, those hearts began to work better.

In fact, they worked just as well as hearts that received stem cells from
marrow, the gold standard for this kind of experiment, he said.

Thii is not in the dream stage anymore. They are about a month away from being
able to store adult stem cells. ONE MONTH! Their 15,000 sq. ft. facility is
almost complete.

They have received and installed a new state-of-the-art CBS Isothermal liquid
nitrogen vapor storage tank and a K Series cryo-storage tank for stem cell
storage.This is an important step toward establishing the Company's Good
Manufacturing Practices (cGMPs) and Good Tissue Practices (cGTP) quality
systems.

The Stem cell industry is experiencing increasing costs to comply with new FDA,
cGMPs, cGTP stem cell requirements. These costs are reducing the number of
competitors, increasing the barriers to entry and better positioning THII as the
leader in the stem cell storage industry.

This is one of the most exciting discoveries ever in my opinion. I don't
believe there is a person on earth that won't benefit sometime in their life
from lifesaving stem cells. Imagine being able to have a minor procedure and
then being able to store your life saving cells that may just save your life in
the future?

THII HIGHLIGHTS

1.) First year revenues to exceed $1 million. Management anticipates continued
surge in year over year revenue growth.

2.) THII receives analyst coverage from Beacon Equity Research with price target
of $6.00. THII currently priced at $2.00.

3.) Float confirmed at 2.7 million with Shares Outstanding at 12.7 million.

4.) Bio-Matrix Scientific focuses on developing leading research and technology
that is patent protected for the purpose of product licensing, which leads to a
continuous revenue stream for the company.

5.) As the market shifts towards disposable tissue management instruments, the
Company believes this will result in over $84 million annually in potential
revenue.

6.) Bio-Matrix Scientific received and installed a new state-of-the-art CBS
Isothermal liquid nitrogen vapor storage tank and a K Series cryo-storage tank
for stem cell storage.This is an important step toward establishing the
Company's Good Manufacturing Practices (cGMPs) and Good Tissue Practices (cGTP)
quality systems. Stem cell industry experiencing increasing costs to comply with
new FDA, cGMPs, cGTP stem cell requirements. These costs are reducing the number
of competitors, increasing the barriers to entry and better positioning THII as
the leader in the stem cell storage industry.

[JJdivini]

www.lifesavingstemcells.com

[JJdivini]

Tasco Holdings Chairman & CEO David Koos Featured in an Audio Interview on Yahoo! Finance Small Cap Centre


(OTC: THII) CEO Featured on Yahoo! Finance Small Cap Centre
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO Circuit.


Aug 28, 2006 7:15:00 AM
LAKE HARMONY, PA -- (MARKET WIRE) -- 08/28/06 -- Tasco Holdings International (OTCBB: THII), the parent company of wholly owned subsidiary Bio-Matrix Scientific Group, Inc. which focuses on stem cell cryogenics and disposable stem cell / tissue transfer instruments, is pleased to announce that Mr. David Koos, Tasco Holdings Chairman and CEO, was recently interviewed by the Yahoo! Small Cap Centre (finance.yahoo.ca).

Mr. Koos discusses a wide range of topics including the growing importance of the Biotechnology sector including the Company's Stem Cell Banking Facility, the recent acquisition of assets, the Company's current and future prospects.

The Yahoo! Finance Canada Small Cap Centre focuses specifically on emerging small cap companies. The Yahoo! Small Cap Centre caters to an audience of small cap investors that are in search of exciting and compelling information within the small cap realm. To access the interview page directly, please click on the link below.

http://cosmos.bcst.yahoo.com/scp_v3/viewer/index.php?pid=16390&rn=222561&cl=649973&ch=22...

[JJdivini]

Showing signs of life !

only a 2.6 million float !

[JJdivini]

on the MOVE !

This can really move on low volume...

[JJdivini]

LOOK AT THIS !!!



***Breaking News Alert***


Company: Tasco Holdings International/DBA Bio-Matrix Scientific Group
Symbol: THII
Current Price: $2.60 (up 62% from $1.60 on 6/21)
Expected Target: $7.70
Status: STRONG BUY
Expectations: 250-450% ROI

The term "forward-looking statements" is defined in Section 27A of the Securities Act of 1933 as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934 as amended the “Exchange Act.” This article’s statements are reasonable;
the company, however, can give no assurance that such expectations will prove different. This article’s forward-looking statements are within the meaning
of the Private Securities Litigation Reform Act of 1995. While Bio-Matrix Scientific Group, Inc. believes its research, performance, forecasting and
assumptions are reasonable, there are some external factors that are hard to predict and influenced by economic and other conditions that can
influence the outcome of performance.

"THII is a $7 to $8 stock. With less than 13 million shares outstanding, THII deserves
capitalization of 75-85 million dollars. Bio-Matrix has made incredible strides and
execute some of the most exciting and innovative concepts in biotechnology. The
process of removing unwanted tissue (fat) and saving it for its stem cell use if the need
arises is a breakthrough step. This will continue to prove itself to be an incredible
investment opportunity." - Mike King, Director of Research

For more information on THII, click on the following links:
http://www.finance.yahoo.com/THII.OB
www.beaconequityresearch.com

This stock is set to explode! Do not wait until it is too late! Buy now.

[JJdivini]

Tasco's Bio-Matrix Scientific Unit Installs New, Cutting-Edge Stem Cell Technology in Preparation for Anticipated September 2006 Grand Opening of Its Stem Cell Cryogenic Banking and Processing Facility

Aug 2, 2006 7:01:00 AM


To Utilize Liquid Nitrogen Vapor Tanks for Storage Testing;
Revenues Anticipated in 4th Quarter of 2006
Tasco Holdings International's (OTCBB:THII) wholly-owned subsidiary Bio-Matrix Scientific Group, Inc. (a Nevada corporation), a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced today that it has received and installed a CBS Isothermal liquid nitrogen vapor storage tank and a K Series cryo-storage tank for stem cell storage.

As Bio-Matrix builds its state-of-the-art stem cell research and storage facility in San Diego, California, the Company will utilize the new CBS V5000 cryo-tank as the flagship for cellular storage at the facility. This new technology will validate central liquid nitrogen supply that feeds all units housed at the Bio-Matrix facility.

"An investment in this new, V-5000 Isothermal Liquid Nitrogen tank and K Series tank allows Bio-Matrix to enter into system testing, which will lead to accepting stem cell storage. This is an important step toward establishing the Company's Good Manufacturing Practices (cGMPs) and Good Tissue Practices (cGTP) quality systems which is an important part of our facility master validation plan that will enhance our ability to provide superior stem cell storage over the long term," said Bio-Matrix Scientific Group Managing Director and COO Brian Pockett.

A Company spokesperson said the Company expects to open the facility for business by the end of September 2006, anticipating revenue in the 4th Quarter of 2006.

Bio-Matrix's new 15,000-sq.-ft., state-of-the-art facility, located in the heart of San Diego, will house the nation's premiere center for stem cell storage, including: Bio-Matrix's secure Cryogenic Stem Cell Bank; four research laboratories; aseptic cellular/tissue processing rooms; and hematology, microbiology and flow cytometry laboratories.

This press release is available on the Company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to [e-mail], where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

[JJdivini]

SAFE, go to www.bigcharts.com

[JJdivini]

StockGuru.com Announces Profile Coverage of Tasco Holdings International
Jul 31, 2006 7:10:00 AM
2006 PrimeZone Media Network

DALLAS, July 31, 2006 (PRIMEZONE) -- John Pentony, Publisher of StockGuru.com, announced today that the web site has initiated Profile Coverage of Tasco Holdings International Inc. (OTCBB:THII). It is a development stage company that recently acquired Bio-Matrix Scientific Group, Inc. The Company is engaged in the cryogenic storage of stem cells and the development of medical devices used in live tissue transfer and stem cell research. Additionally, the Company has developed 192 disposable instruments for use in plastic surgery, tissue management and stem cell research. These instruments have been designed to harvest adult stem cells from adipose tissue. The company plans to commercialize these instruments to plastic surgeons and patients to help store stem cells derived from their adipose tissue (extracted primarily during the liposuction process).

To view the StockGuru.com Profile for Tasco Holdings International Inc., please visit:

http://www.stockguru.com/profiles/thii/index.php

[Safemaster]

StockCharts don't have a chart on it yet.

[JJdivini]

Looking good today !

[JJdivini]

Tasco Holdings International Rated 'Outperform,' Target $6.00 by Beacon Equity Research
Jul 26, 2006 7:07:00 AM



Tasco Holdings International (OTCBB: THII) has been rated "Outperform" with a target price of $6.00 by Beacon Equity Senior Research Analyst, Kris Goldcross, CFA.

The full report is available at
http://www.BeaconEquityResearch.com

In the report Mr. Goldcross writes, "The Company is engaged in the cryogenic storage of non-controversial stem cells and the development of medical devices used in live tissue transfer and stem cell research. Additionally, the Company has developed 192 disposable instruments for use in plastic surgery, tissue management and stem cell research. The company plans to commercialize these instruments to plastic surgeons and patients to efficiently help store stem cells.

"Since currently the company has significant exposure in the stem cell banking operations, we have compared the market value of Tasco with other major operators in the industry including Cord Blood America (OTCBB: CBAI); Viacell, Inc. (Nasdaq: VIAC); StemCells, Inc. (Nasdaq: STEM); Aastrom Biosciences, Inc. (Nasdaq: ASTM); Geron Corporation; Regeneration Technologies; Cryo-Cell International, Inc.; and Thermogenics, Corp."

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of Tasco Holdings International (THII). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon has directly been compensated seven-thousand dollars by a non-controlling third-party shareholder of Tasco International for enrollment in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.

Anyone interested in receiving alerts regarding Tasco Holdings International research should email [e-mail] with "THII" in the subject line.

[JJdivini]

Tasco Holdings International Favorably Profiled in OTC Financial Network Report
Jul 25, 2006 8:30:00 AM
Copyright Business Wire 2006
SAN DIEGO--(BUSINESS WIRE)--July 25, 2006--

Tasco Holdings International (OTCBB:THII), a biotechnology company focused on stem cell cryogenics and disposable stem cell / tissue transfer instruments, announced today that OTC Financial Network, a division of National Financial Communications Corp., has issued an Investor Facts report on the Company.

The report includes a profile of Tasco Holdings' unique market opportunities, comprehensive business plan, future growth prospects and investment considerations.

Interested parties can view the report online at: http://www.otcfn.com/thii/report.html or call 781.444.6100 for reprints.

Geoffrey Eiten, president of National Financial Communications, said, "With worldwide spending on medical research and technology growing at enormous rates -- more than $14 billion in public and private funds is expected to be spent on stem cell research alone this year -- agencies, such as those that offer stem cell research and related products, services and facilities stand to benefit over the near and long term. And their market positioning couldn't be timelier to public funding debates.

"Having already invested substantial capital to construct and outfit a first-of-its-kind 15,000 square foot, FDA-compliant cGMP (Good Manufacturing Practices) and cGTP (Good Tissue Practices) facility for adult stem cell storage and research in the U.S., Tasco is uniquely positioned to capture its share of the estimated $75 billion a year biotech and medical device industry."

[JJdivini]

http://www.otcfn.com/thii/index.html

[JJdivini]

Tasco Holdings International Retains OTC Financial Network for Comprehensive Investor Relations CampaignadvertisementRelated information E-mail this article Print-friendly versionStocks mentioned in this articleTASCO HOLDINGS INTERNATIONAL INC(THII) Quote, Chart, News


All Business Wire NewsTasco Holdings International THII, a biotechnology company focused on stem cell cryogenics and disposable stem cell / tissue transfer instruments, announced today that it has retained OTC Financial Network, a division of National Financial Communications (NFC) Corporation, for a comprehensive investor relations campaign.


Related newsBio-Matrix Scientific Group Inc. Announces Completion Sale of Wholly Owned Subsidiary and Operating Entity to Tasco Holdings International, Inc.
NFC President Geoffrey Eiten said, "By developing or acquiring patented or proprietary technologies that can be converted into steady revenue streams, either by manufacturing products or licensing technology, Tasco Holdings is operating a unique business model that will allow for substantial growth over the near and long term."

Eiten continued, "Having recently purchased Bio-Matrix Scientific Group, an emerging leader in the stem cell storage and research segment of the $75 billion biotech and medical device industry, Tasco Holdings is uniquely situated for introduction to the financial community. We look forward to working with Tasco to expand its access to Wall Street and create market awareness for this emerging biotech leader."

Tasco Holdings Inc. recently acquired 100% of Bio-Matrix Scientific Group, a biotech research and development company focused on the growing, worldwide market for stem cell research service providers.

About Tasco Holdings International Inc.

Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

About OTC Financial Network

Since 1992, OTC Financial Network (www.otcfn.com) has provided consulting services and customized, proactive investor relations campaigns to more than 500 small/micro-cap public companies. The Company designs and implements results-driven direct mail, electronic marketing, shareholder communications and other programs to increase market awareness on behalf of its clients.

A partnership with OTC Financial Network can improve shareholder communications channels, facilitate capital formation opportunities, create an expanding and diversified base of institutional and retail shareholders, and garner media coverage. OTC Financial Network is a division of National Financial Communications Corp. based in Needham, MA. For more information visit www.otcfn.com and www.nationalfc.com.

Disclaimer: OTC Financial Network serves as special advisor to Tasco Holdings and has received fees for services, including $7500.00 per month paid by a third party, plus 200,000 options at an exercise price of $4.50 paid by the Company. These underlying securities have not been registered pursuant to the Securities Act of 1933, as amended (the "Securities Act"), and therefore may not be sold or transferred by Company except in the event that such shares are the subject of a registration statement. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. Additional compensation information and a full disclaimer can be found online by visiting http://www.otcfn.com/thii and selecting the "Disclaimer" link.

[JJdivini]

LOS ANGELES, CA -- (MARKET WIRE) -- 07/21/06 -- MoneyTV is the nationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews by hosts Donald Baillargeon and Skip Lindeman with company CEOs, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to [e-mail].

The television program can also be viewed online immediately at www.moneytv.net.

Featured companies on this week's show include:

Tasco Holdings International, Inc. (OTCBB: THII) C.O.O. Brian Pockett discussed the company's cryogenic collection and storage of adult stem cells.

XsunX, Inc. (OTCBB: XSNX) CEO Tom Djokovich spoke further of the company's recent volatility in their stock price.

Creator Capital, Ltd. (PINKSHEETS: CTORF) CEO Alex Downie discussed the potential of recent deals entered into.

Baltia Air Lines, Inc. VP Robert Strom spoke of luxury retrofits to their 747 jumbo jet.

Cord Blood America, Inc. CEO Matt Schissler discussed ramifications of President Bush's recent veto of the Stem Cell Federal Funding Bill.

Semotus Solutions, Inc. CEO Anthony Lapine debunked rumors surrounding the recent letter received from the American Stock Exchange.

Manhattan West Mortgage CEO Roger Schlesinger explained that 100% financing can be obtained with a credit score as low as 580.

Viewers of MoneyTV can receive free information in the mail about featured companies by calling the toll-free phone number on their TV screen. The weekly television program debuted in 1996 and is broadcast nationally in the USA to 70 million U.S. homes on Saturdays at 11:00 AM ET, Sundays at 8:30AM PT, 8:30AM ET, 9:30 AM ET, 3:30PM ET and Mondays at 6:30 PM ET.

MoneyTV is broadcast to 45 million TV homes in Western Europe, Wednesdays at 7:30 PM.

MoneyTV is also broadcast on UPN-TV in the Virgin Islands and Puerto Rico Sundays at 8:00 AM.

A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net

MoneyTV television program, Copyright MMVI, all rights reserved. MoneyTV does not provide an analysis of companies' financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3 to 4 month corporate profile with multiple appearances for a cash fee of $11,500.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by the producers, publisher or parent company of MoneyTV.

Contact:
Donald Baillargeon
Executive Producer
MoneyTV
949 388 5267
[e-mail]